glucotrol xl glipizide extended release tablet 5mg per tablet 14tablets per carton

Description

Indication & Scope

Glucotrol XL® is a prescription second-generation sulfonylurea indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when lifestyle interventions alone are insufficient. It can be used as monotherapy or in combination with other antidiabetic agents, including metformin, insulin, and DPP-4 inhibitors. The osmotic pump controlled-release formulation provides gradual drug release over 24 hours, allowing once-daily dosing.

Mechanism: Glipizide stimulates insulin secretion from pancreatic β-cells by closing ATP-sensitive potassium channels, increasing insulin release and lowering blood glucose.
Drug class: Second-generation sulfonylurea.
Clinical use: Monotherapy or combination therapy for adults with type 2 diabetes mellitus requiring improved glycemic control.

Specification

Generic Name	Glipizide Extended Release Tablets
Brand Name	Glucotrol XL®
Ingredient	Glipizide
Dosage Form	Extended Release Tablet
Package	5 mg/tablet, 14 tablets/carton
Conditions Treated	Adults with type 2 diabetes mellitus requiring improved glycemic control when diet, exercise, and weight management alone are insufficient, either as monotherapy or in combination with other antidiabetic medications.
Taboos	Hypersensitivity to glipizide, sulfonylureas, or sulfonamides; type 1 diabetes mellitus; diabetic ketoacidosis; hyperosmolar hyperglycemic coma; severe hepatic or renal impairment.
Place of origin	USA
Prescription type	Prescription Drug (Rx)
Storage Conditions	Store below 25°C in a dry place, protected from moisture.
Manufacturer	Viatris Pharmaceuticals LLC
Registration Authority	National Medical Products Administration (NMPA), China
Approval Number	HJ20160139
Approval Date	October 14, 2024
Shelf Life	36 months

How to use ?

Recommended Dose: The usual starting dose is 5 mg once daily. The dose may be gradually increased according to blood glucose response. The maximum recommended daily dose is 20 mg.

Time: Take once daily before breakfast.

Instructions for use: Swallow the tablet whole. Do not crush, chew, or split. The empty tablet shell may appear in stools and is a normal result of the controlled-release system.

Interaction: The risk of hypoglycemia may increase when combined with insulin or other glucose-lowering agents. Corticosteroids, thyroid hormones, and some diuretics may reduce the glucose-lowering effect.

Side effects: Common adverse reactions include hypoglycemia, nausea, abdominal discomfort, dizziness, headache, and skin reactions.

Important Notice

This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indication, and regional regulatory requirements.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support

Certificate of Analysis

GMP Certificate

Commercial Invoice

Packing List & CPP

Cold Chain Logistics

Customs Documentation

Scientific and regulatory sources

1.WHO References

2.NMPA

3.FDA

4.EMA

FAQ

What is Glucotrol XL® used for?

Glucotrol XL® is used to improve blood glucose control in adults with type 2 diabetes mellitus when diet and exercise alone are insufficient.

How should Glucotrol XL® be taken?

It is usually taken once daily before breakfast and should be swallowed whole.

Can the tablet be crushed or split?

No. Glucotrol XL® uses an osmotic pump controlled-release system and should not be crushed, chewed, or split.

Why may an empty tablet shell appear in stool?

The tablet shell is designed to release the active ingredient and may pass through the digestive system after drug release. This is normal and does not indicate treatment failure.